Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval

Core Viewpoint - The FDA's approval of Vanda's drug Nereus marks a significant advancement in preventing motion-induced vomiting, which may also provide a new treatment avenue for nausea associated with GLP-1 weight-loss medications [1] Group 1 - Vanda's drug Nereus is specifically designed to prevent motion-induced vomiting [1] - The approval by the FDA opens potential opportunities for the drug to be used in treating nausea linked to GLP-1 weight-loss drugs [1]